Login to Your Account

Following SPA OK, Achaogen seeks $75M and listing as ‘AKAO’

By Jennifer Boggs
Managing Editor

Monday, January 27, 2014
Set to start its Phase III trial for antibacterial candidate plazomicin this quarter, Achagoen Inc. filed for a $74.8 million initial public offering (IPO), which, along with anticipated funding from the Biomedical Advanced Research and Development Authority (BARDA), could take the firm through top-line data, expected in the first half of 2017.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription